Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

23.03.2016 | Case Report

Rare Occurrence of 3 “H”: Hypercalcemia, Hemolytic Anemia and Hodgkin’s Lymphoma

verfasst von: Ankur Jain, Pankaj Malhotra, Gaurav Prakash, Subhash Varma, Narender Kumar, Asim Das

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Clinicians in hematology practice commonly encounter anemia, hypercalcemia and renal failure, which when present in combination evoke a diagnostic workup for multiple myeloma. We report a 71-years old lady who presented to our hematology clinic with fever and easy fatiguability of 3 months duration and on investigations was found to have anemia and hypercalcemia. Direct Coomb’s test characterized the anemia as complement mediated (anti-C3d) hemolysis. Biochemical investigations revealed normal 25(OH) Vitamin D3 and suppressed Parathormone levels and a negative workup for plasma cell dyscrasias, sarcoidosis and autoimmune disorders. CT scan revealed a paravertebral mass with cervical, supraclavicular and abdominal lymphadenopathy along with splenomegaly and left pleural effusion. Biopsy from the paravertebral mass confirmed the diagnosis of Hodgkin’s disease (nodular sclerosis) using immunohistochemistry. Bone marrow examination suggested infiltration by lymphoma. Hypercalcemia was managed with saline and zoledronic acid. Administration of prednisolone (1 mg/kg/day) along with chemotherapy (ABVD regimen) led to normalization of calcium and hemoglobin levels. However, hemolysis recurred 2 weeks later and hence, Rituximab (375 mg/m2) was administered on a weekly schedule for 4 doses and ABVD (2 weekly) was continued, which brought hemolysis under control. Co-occurrence of two paraneoplastic manifestations (complement mediated hemolytic anemia and hypercalcemia) in Hodgkin’s lymphoma is very unusual. Present report aims not only to highlight a rare presentation of Hodgkin’s lymphoma but also focus on the role of Rituximab in controlling hemolysis associated with this disease.
Literatur
1.
Zurück zum Zitat Eisner E, Ley AB, Mayer K (1967) Coomb’s-positive hemolytic anemia in Hodgkin’s disease. Ann Intern Med 66:258–273CrossRefPubMed Eisner E, Ley AB, Mayer K (1967) Coomb’s-positive hemolytic anemia in Hodgkin’s disease. Ann Intern Med 66:258–273CrossRefPubMed
2.
Zurück zum Zitat Linde R, Basso L (1987) Hodgkin’s disease with hypercalcemia detected by thallium-201 scintigraphy. J Nucl Med 28:112–115PubMed Linde R, Basso L (1987) Hodgkin’s disease with hypercalcemia detected by thallium-201 scintigraphy. J Nucl Med 28:112–115PubMed
3.
Zurück zum Zitat Levine AM, Thornton P, Forman SJ, Van Hale P, Holdorf D, Rouault CL, Powars D et al (1980) Positive Coombs test in Hodgkin’s disease: significance and implications. Blood 55:607–611PubMed Levine AM, Thornton P, Forman SJ, Van Hale P, Holdorf D, Rouault CL, Powars D et al (1980) Positive Coombs test in Hodgkin’s disease: significance and implications. Blood 55:607–611PubMed
4.
Zurück zum Zitat Seymour JF, Gagel RF (1993) Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non Hodgkin’s lymphomas. Blood 82:1383–1394PubMed Seymour JF, Gagel RF (1993) Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non Hodgkin’s lymphomas. Blood 82:1383–1394PubMed
5.
Zurück zum Zitat Giannopoulos P, Bergsagel DE (1959) The mechanism of the anemia associated with Hodgkin’s disease. Blood 14:856–869PubMed Giannopoulos P, Bergsagel DE (1959) The mechanism of the anemia associated with Hodgkin’s disease. Blood 14:856–869PubMed
6.
Zurück zum Zitat Gellhorn A, Plimpton CH (1956) Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med 21:750–759CrossRefPubMed Gellhorn A, Plimpton CH (1956) Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med 21:750–759CrossRefPubMed
7.
Zurück zum Zitat Karmali R, Barker S, Hewison M, Fraher L, Katz DR, O’Riordan JL (1990) Intermittent hypercalcemia and vitamin D sensitivity in Hodgkin’s disease. Postgrad Med J 66:757–760CrossRefPubMedPubMedCentral Karmali R, Barker S, Hewison M, Fraher L, Katz DR, O’Riordan JL (1990) Intermittent hypercalcemia and vitamin D sensitivity in Hodgkin’s disease. Postgrad Med J 66:757–760CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Adams JS (1989) Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin N Am 18:765–778 Adams JS (1989) Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin N Am 18:765–778
9.
Zurück zum Zitat Krakauer T, Oppenhaim JJ (1993) IL-1 and tumor necrosis factor α each up-regulate both the expression of IFN-γ receptors and enhance IFN-γ induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). J Immunol 150:1205–1211PubMed Krakauer T, Oppenhaim JJ (1993) IL-1 and tumor necrosis factor α each up-regulate both the expression of IFN-γ receptors and enhance IFN-γ induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). J Immunol 150:1205–1211PubMed
10.
Zurück zum Zitat Adams ND, Gray RW, Lemann J Jr, Cheung HS (1982) Effects of calcitriol administration on calcium metabolism in healthy men. Kidney Int 21:90–97CrossRefPubMed Adams ND, Gray RW, Lemann J Jr, Cheung HS (1982) Effects of calcitriol administration on calcium metabolism in healthy men. Kidney Int 21:90–97CrossRefPubMed
Metadaten
Titel
Rare Occurrence of 3 “H”: Hypercalcemia, Hemolytic Anemia and Hodgkin’s Lymphoma
verfasst von
Ankur Jain
Pankaj Malhotra
Gaurav Prakash
Subhash Varma
Narender Kumar
Asim Das
Publikationsdatum
23.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe Sonderheft 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0672-0

Weitere Artikel der Sonderheft 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.